

FOI 3785

9th June 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

Response:

Current patients as of 22/05/26

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	27	7
Adalimumab [All Biosimilars]	327	257
Apremilast [Otezla]	0	0
Apremilast [Generic]	0	0
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	<5	<5
Infliximab [Remicade]	0	0
Infliximab [All Biosimilars]	11	<5
Ustekinumab [Stelara]	<5	<5
Ustekinumab [All Biosimilars]	25	23
Bimekizumab [Bimzelx]	20	20
Brodalumab [Kyntheum]	5	5
Certolizumab [Cimzia]	7	7
Deucravacitinib [Sotyktu]	0	0
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	69	69
Ixekizumab [Taltz]	117	117
Risankizumab [Skyrizi]	142	142
Secukinumab [Cosentyx]	52	29

Spesolimab [Spevigo]	0	0
Tildrakizumab [Ilumetri]	5	5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

Response:

Current patients as of 22/05/26

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	93		93	0
Adalimumab [Humira]	25	13	<5	9
Adalimumab [All Biosimilars]	700	228	216	242
Apremilast [Otezla]	0			0
Apremilast [Generic]	0			0
Baricitinib [Olumiant]	31		31	
Bimekizumab [Bimzelx]	8	<5		6
Certolizumab [Cimzia]	78	26	18	33
Etanercept [Enbrel]	9	0	5	<5
Etanercept [All Biosimilars]	226	38	118	64
Filgotinib [Jyseleca]	0		0	

Golimumab [Simponi]	72	29	16	27
Golimumab [All Biosimilars]	0	0	0	0
Guselkumab [Tremfya]	15		0	15
Infliximab [Remicade]	<5	0	0	0
Infliximab [All Biosimilars]	Figures not available as yet so information not held	Figures not available as yet so information not held	Figures not available as yet so information not held	Figures not available as yet so information not held
Ixekizumab [Taltz]	79	22		57
Risankizumab [Skyrizi]	<5			<5
Rituximab [MabThera]	Figures not available as yet so information not held		Figures not available as yet so information not held	
Rituximab [Biosimilars]	Figures not available as yet so information not held		Figures not available as yet so information not held	
Sarilumab [Kevzara]	20		20	
Secukinumab [Cosentyx]	163	64		98
Tocilizumab [RoActemra]	25		14	
Tocilizumab [Biosimilars]	39		28	
Tofacitinib [Xeljanz]	6	0	<5	<5
Upadacitinib [Rinvoq]	40	9	22	9
Ustekinumab [Stelara]	<5			<5
Ustekinumab Biosimilar	0			0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Email: foi.team@southerntrust.hscni.net